Introduce Lurbinectedin in Periph Vein, Perc, New Tech 7

This code describes the administration of the antineoplastic drug Lurbinectedin directly into a peripheral vein. This procedure is performed using a percutaneous approach, meaning through the skin, typically via a needle or catheter inserted into a superficial vein. The "New Technology Group 7" designation indicates that Lurbinectedin is a recently approved or innovative therapeutic agent.

This code is used when Lurbinectedin is administered intravenously for the treatment of metastatic small cell lung cancer (SCLC) in adult patients with disease progression on or after platinum-based chemotherapy. It specifically applies to the infusion of this drug into a peripheral vein, such as in the arm or hand, rather than a central venous access device.

• Ensure documentation specifies Lurbinectedin as the substance introduced.
• Verify the administration route is peripheral intravenous and not central.
• Confirm the procedure is for therapeutic purposes, typically for cancer treatment.